Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Critical Care

Figure 4

From: Clinical review: Early treatment of acute lung injury - paradigm shift toward prevention and treatment prior to respiratory failure

Figure 4

Effects of simvastatin on pulmonary and nonpulmonary organ function. Patients with acute lung injury/acute respiratory distress syndrome were treated with 80 mg simvastatin (gray bars) or placebo (white bars). (a) Simvastatin reduces oxygenation index (OI) at day 14 but does not reach statistical significance. Data are mean and standard deviation. (b) Simvastatin reduces plateau pressure at day 14 but does not reach statistical significance. Data are mean and standard deviation. (c) Simvastatin reduces lung injury score (LIS) at day 14 but does not reach statistical significance. Data are mean and standard deviation. (d) Simvastatin reduces Sequential Organ Failure Assessment (SOFA) score at day 14. Data are median (interquartile range). *P < 0.05 versus placebo. Reprinted from [64] with permission of the American Thoracic Society. Copyright © 2012 American Thoracic Society. Official Journal of the American Thoracic Society.

Back to article page